Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics

Revision as of 15:54, 27 August 2018 by Mahda (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Glucose-6-phosphate dehydrogenase deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Glucose-6-phosphate dehydrogenase deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics

CDC on Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics

Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics in the news

Blogs on Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics

Directions to Hospitals Treating Glucose-6-phosphate dehydrogenase deficiency

Risk calculators and risk factors for Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahda Alihashemi M.D. [2]

Overview

G6PD deficiency is affecting 400 million people worldwide. atients of all age groups may develop favism, but more often and severe in childern. African, Middle Eastern and South Asian people are affected the most. Men are more commonly affected by G6PD deficiency.

Epidemiology and Demographics

Prevalence

  • G6PD deficiency is affecting 400 million people worldwide. [1]

Case-fatality rate/Mortality rate

  • G6PD deficiency resulted in 4,100 deaths in 2013 and 3,400 deaths in 1990[2]

Age

  • Patients of all age groups may develop favism (acute hemolytic anemia from eating fava beans ), but more often and severe in childern.

Race

  • African, Middle Eastern and South Asian people are affected the most.

Gender

  • Men are more commonly affected by G6PD deficiency than women, because it is an X-linked recessive disorder.

Region

  • The majority of G6PD deficiency cases are reported in African, Middle Eastern and South Asian people. [3]

References

  1. Mason PJ, Bautista JM, Gilsanz F (September 2007). "G6PD deficiency: the genotype-phenotype association". Blood Rev. 21 (5): 267–83. doi:10.1016/j.blre.2007.05.002. PMID 17611006.
  2. "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013". Lancet. 385 (9963): 117–71. January 2015. doi:10.1016/S0140-6736(14)61682-2. PMC 4340604. PMID 25530442.
  3. Beutler E (January 1991). "Glucose-6-phosphate dehydrogenase deficiency". N. Engl. J. Med. 324 (3): 169–74. doi:10.1056/NEJM199101173240306. PMID 1984194.